This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.
Newly treated female patients aged ≥18 years and ≤75 years;
ECOG score 0~1;
Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T≥2cm or lymph node positive;
Hormone receptor status (ER and PgR) is known, where ER≥10%
Stage IV (metastatic) breast cancer;
Inflammatory breast cancer;
Previous antitumor therapy or radiation therapy for any malignancies, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma;
Also receiving antitumor therapy in other clinical trials, including endocrine therapy, bisphosphonate therapy, or immunotherapy;
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead sponsor